Vidofludimus is primarily investigated for its anti-inflammatory and immunomodulatory properties, making it a candidate for treating autoimmune and inflammatory diseases. It has been studied in clinical trials for conditions such as ulcerative colitis and rheumatoid arthritis, where it helps reduce disease activity by modulating immune responses. Its mechanism involves inhibition of key enzymes in the pyrimidine synthesis pathway, thereby suppressing the proliferation of activated immune cells. Due to its oral bioavailability and favorable safety profile in early studies, it offers potential as a treatment option in chronic inflammatory disorders with a need for long-term therapy. Research is also exploring its role in neurodegenerative and viral diseases, including investigations into its effects on multiple sclerosis and antiviral activity.